Definition

A preparation of human T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20, CD22 and CD30, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22/CD30 CAR-T cells target and bind to CD19, CD20, CD22 and CD30 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.